Ironwood Pharmaceuticals Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Ironwood Pharmaceuticals Inc. has filed its 2023 10-K report detailing its fiscal year performance and business operations.</b>

AI Summary

IRONWOOD PHARMACEUTICALS INC (IRWD) filed a Annual Report (10-K) with the SEC on February 16, 2024. Ironwood Pharmaceuticals Inc. filed its 2023 Form 10-K on February 16, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal business address is 100 Summer Street, Suite 2300, Boston, MA 02110. Ironwood Pharmaceuticals Inc. is classified under Pharmaceutical Preparations (SIC 2834). The filing includes details on various equity incentive plans and stock-based compensation arrangements.

Why It Matters

For investors and stakeholders tracking IRONWOOD PHARMACEUTICALS INC, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Ironwood's financial health, operational strategies, and risk factors for the fiscal year 2023, crucial for investors to assess the company's current standing and future prospects. The detailed information on equity incentive plans and stock-based compensation offers insight into the company's approach to employee remuneration and potential dilution for shareholders.

Risk Assessment

Risk Level: medium — IRONWOOD PHARMACEUTICALS INC shows moderate risk based on this filing. The company operates in the pharmaceutical industry, which is subject to significant regulatory oversight, patent expirations, and intense competition, posing inherent risks to revenue and profitability.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand the company's performance and potential challenges in the pharmaceutical market.

Key Numbers

• 2023-12-31 — Fiscal Year End (Period covered by the 10-K filing)
• 2024-02-16 — Filing Date (Date the 10-K was filed with the SEC)
• 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)

Key Players & Entities

• IRONWOOD PHARMACEUTICALS INC (company) — Filer name
• 2024-02-16 (date) — Filing date
• 2023-12-31 (date) — Fiscal year end
• 100 SUMMER STREET, SUITE 2300 (address) — Business address
• BOSTON (location) — Business address city
• MA (location) — Business address state
• 02110 (postal_code) — Business address zip
• 617-621-7722 (phone_number) — Business phone

FAQ

Risk Factors

• Regulatory Environment [high — regulatory]: The pharmaceutical industry is subject to extensive regulation by government agencies, impacting product development, marketing, and sales.
• Competition [high — market]: The company faces significant competition from other pharmaceutical companies, which can affect market share and pricing.
• Intellectual Property and Patents [medium — financial]: Reliance on patent protection for key products is critical; patent expirations or challenges can lead to revenue loss.

Key Dates

• 2024-02-16: 10-K Filing — Official filing of the annual report for the fiscal year 2023.

Key Financial Figures

• $400.0 million — o Acquisition was partially funded with $400.0 million of borrowings under a new revolving cre
• $430.5 million — flow. Maximize LINZESS We recognized $430.5 million in collaborative arrangements revenue r
• $31.7 million — nded December 31, 2023, a n increase of $31.7 million compared to the year ended December 31,
• $1.0 b — recognized a net loss of approximately $1.0 billion, which included a non-recurring c
• $1.1 billion — a non-recurring charge of approximately $1.1 billion for acquired in-process research and de
• $183.4 million — he VectivBio Acquisition. We generated $183.4 million in cash from operations during the year
• $92.2 million — December 31, 2023, ending the year with $92.2 million in cash and cash equivalents. 6 Tabl

Filing Documents

• irwd-20231231x10k.htm (10-K) — 3480KB
• irwd-20231231xex10d9.htm (EX-10.9) — 38KB
• irwd-20231231xex21d1.htm (EX-21.1) — 2KB
• irwd-20231231xex23d1.htm (EX-23.1) — 12KB
• irwd-20231231xex31d1.htm (EX-31.1) — 13KB
• irwd-20231231xex31d2.htm (EX-31.2) — 13KB
• irwd-20231231xex32d1.htm (EX-32.1) — 7KB
• irwd-20231231xex32d2.htm (EX-32.2) — 7KB
• irwd-20231231xex97d1.htm (EX-97.1) — 39KB
• irwd-20231231x10k002.jpg (GRAPHIC) — 65KB
• irwd-20231231x10k003.jpg (GRAPHIC) — 63KB
• 0001558370-24-001275.txt (&nbsp;) — 17309KB
• irwd-20231231.xsd (EX-101.SCH) — 131KB
• irwd-20231231_cal.xml (EX-101.CAL) — 113KB
• irwd-20231231_def.xml (EX-101.DEF) — 555KB
• irwd-20231231_lab.xml (EX-101.LAB) — 979KB
• irwd-20231231_pre.xml (EX-101.PRE) — 953KB
• irwd-20231231x10k_htm.xml (XML) — 3096KB

Business

Business 5 Item 1A.

Risk Factors

Risk Factors 26 Item 1B. Unresolved Staff Comments 60 Item 1C. Cybersecurity 61 Item 2.

Properties

Properties 61 Item 3.

Legal Proceedings

Legal Proceedings 61 Item 4. Mine Safety Disclosures 61 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 62 Item 6.

Selected Financial Data

Selected Financial Data 63 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 64 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 79 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 80 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 80 Item 9A.

Controls and Procedures

Controls and Procedures 80 Item 9B. Other Information 83 PART III Item 10. Directors, Executive Officers and Corporate Governance 83 Item 11.

Executive Compensation

Executive Compensation 83 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 83 Item 13. Certain Relationships and Related Transactions, and Director Independence 84 Item 14. Principal Accountant Fees and Services 84 PART IV Item 15. Exhibits and Financial Statement Schedules 85 Item 16. Form 10-K Summary 91

Signatures

Signatures 92 Index to Consolidated Financial Statements F-1 5 Table of Contents PART I

Business

Item 1. Business Our Company We are a gastrointestinal, or GI, healthcare company dedicated to advancing the treatment of GI diseases and redefining the standard of care for GI patients. We are focused on the development and commercialization of innovative GI product opportunities in areas of significant unmet need, leveraging our demonstrated expertise and capabilities in GI diseases. LINZESS (linaclotide), our commercial product, is the first product approved by the United States Food and Drug Administration, or U.S. FDA, in a class of GI medicines called guanylate cyclase type C agonists, or GC-C agonists, and is indicated for adult men and women suffering from irritable bowel syndrome with constipation, or IBS-C, or chronic idiopathic constipation, or CIC, and for pediatric patients ages 6-17 years-old suffering from functional constipation, or FC. LINZESS is available to adult men and women suffering from IBS-C or CIC in the United States, or the U.S., Mexico, and Saudi Arabia, to adult men and women suffering from IBS-C or chronic constipation in Japan, IBS-C in China and for pediatric patients ages 6-17 with FC in the U.S. Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries. We have strategic partnerships with leading pharmaceutical companies to support the development and commercialization of linaclotide throughout the world, including with AbbVie Inc. (together with its affiliates), or AbbVie, in the U.S. and all countries worldwide other than China (including Hong Kong and Macau) and Japan, AstraZeneca AB (together with its affiliates), or AstraZeneca, in China (including Hong Kong and Macau) and Astellas Pharma Inc., or Astellas, in Japan. We also aim to leverage our leading development and commercialization capabilities in GI to bring additional treatment options to GI patients. In June 2023, we

View Full Filing

View this 10-K filing on SEC EDGAR